Evidence map›Paper›PMID 39762080›Full record

ArticleJournal for immunotherapy of cancer2025

Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression.

Kaifeng Jin, Yawei Ding, Jingtong Xu, Zhaopei Liu, Han Zeng, Xiaohe Su, Lingkai Zhang, Jiaxing Sun, Yuzhen Wu, Hailong Liu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kaifeng Jin *Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-9867-6516
Yawei Ding *Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jingtong Xu *Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Zhaopei Liu *NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-5288-5037
Han Zeng *Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.ORCID http://orcid.org/0000-0001-6486-2038
Xiaohe SuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Lingkai ZhangNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jiaxing SunDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Yuzhen WuDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Hailong LiuDepartment of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuan ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yu ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zewei WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China zwwang12@fudan.edu.cn xl11887@rjh.com.cn weijuanzhang@fudan.edu.cn jjxufdu@fudan.edu.cn.ORCID http://orcid.org/0000-0002-8833-3541
Le XuDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China zwwang12@fudan.edu.cn xl11887@rjh.com.cn weijuanzhang@fudan.edu.cn jjxufdu@fudan.edu.cn.
Weijuan ZhangDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China zwwang12@fudan.edu.cn xl11887@rjh.com.cn weijuanzhang@fudan.edu.cn jjxufdu@fudan.edu.cn.ORCID http://orcid.org/0000-0003-3494-3114
Jiejie XuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China zwwang12@fudan.edu.cn xl11887@rjh.com.cn weijuanzhang@fudan.edu.cn jjxufdu@fudan.edu.cn.ORCID http://orcid.org/0000-0001-7431-9063

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe E3 ubiquitin ligase murine double minute 2 (MDM2) binds the p53 transcriptional activation domain and acts as a potent inhibitor of

methodsThis study analyzed 240 patients with UC with matched clinical annotations from two local cohorts (ZSHS cohort and FUSCC cohort). We assessed the correlation between

results

conclusions

Indexed as

Drug Resistance, NeoplasmImmunotherapyProto-Oncogene Proteins c-mdm2AgedFemaleGene AmplificationHumansMaleMiddle AgedUrinary Bladder NeoplasmsMDM2 protein, humanProto-Oncogene Proteins c-mdm2Bladder CancerChemotherapyGenitourinary CancerImmune Checkpoint InhibitorTumor microenvironment - TME

Identifiers

PMID39762080
PMCPMC11749520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.